These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 22402123

  • 1. ERK inhibition overcomes acquired resistance to MEK inhibitors.
    Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.
    Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
    [Abstract] [Full Text] [Related]

  • 2. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
    Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA.
    Sci Signal; 2010 Nov 23; 3(149):ra84. PubMed ID: 21098728
    [Abstract] [Full Text] [Related]

  • 3. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI, Solit DB.
    Sci Signal; 2011 Mar 29; 4(166):pe16. PubMed ID: 21447797
    [Abstract] [Full Text] [Related]

  • 4. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X, Tang Z, Du R, Yao Z, Cheung SH, Zhang X, Wei J, Zhao Y, Du Y, Liu Y, Hu X, Gong W, Liu Y, Gao Y, Huang Z, Cao Z, Wei M, Zhou C, Wang L, Rosen N, Smith PD, Luo L.
    Mol Oncol; 2020 Aug 29; 14(8):1833-1849. PubMed ID: 32336014
    [Abstract] [Full Text] [Related]

  • 5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.
    Cancer Discov; 2015 Apr 29; 5(4):358-67. PubMed ID: 25673644
    [Abstract] [Full Text] [Related]

  • 6. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.
    Cancer Discov; 2013 Jul 29; 3(7):742-50. PubMed ID: 23614898
    [Abstract] [Full Text] [Related]

  • 7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 29; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 8. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B, Ritt DA, Morrison DK, Der CJ, Cox AD.
    J Biol Chem; 2016 Aug 19; 291(34):17804-15. PubMed ID: 27226552
    [Abstract] [Full Text] [Related]

  • 9. In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.
    Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE.
    Mol Cancer Ther; 2019 Sep 19; 18(9):1637-1648. PubMed ID: 31270153
    [Abstract] [Full Text] [Related]

  • 10. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
    Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, Jücker M, Ewald F.
    Cell Signal; 2015 Nov 19; 27(11):2191-200. PubMed ID: 26210887
    [Abstract] [Full Text] [Related]

  • 11. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 19; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

  • 12. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.
    Proc Natl Acad Sci U S A; 2010 Aug 17; 107(33):14903-8. PubMed ID: 20668238
    [Abstract] [Full Text] [Related]

  • 13. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H.
    J Invest Dermatol; 2012 Jul 23; 132(7):1850-9. PubMed ID: 22437314
    [Abstract] [Full Text] [Related]

  • 15. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S, Flaherty KT.
    Expert Rev Mol Med; 2012 Oct 12; 14():e17. PubMed ID: 23058743
    [Abstract] [Full Text] [Related]

  • 16. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA.
    Mol Cancer Ther; 2015 Dec 12; 14(12):2700-11. PubMed ID: 26351322
    [Abstract] [Full Text] [Related]

  • 17. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.
    Nature; 2010 Mar 18; 464(7287):427-30. PubMed ID: 20179705
    [Abstract] [Full Text] [Related]

  • 18. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.
    Nature; 2010 Mar 18; 464(7287):431-5. PubMed ID: 20130576
    [Abstract] [Full Text] [Related]

  • 19. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
    Jaiswal BS, Durinck S, Stawiski EW, Yin J, Wang W, Lin E, Moffat J, Martin SE, Modrusan Z, Seshagiri S.
    Clin Cancer Res; 2018 Aug 15; 24(16):4044-4055. PubMed ID: 29760222
    [Abstract] [Full Text] [Related]

  • 20. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.
    J Clin Endocrinol Metab; 2008 Jun 15; 93(6):2194-201. PubMed ID: 18381570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.